{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:27:13Z","timestamp":1791358033472,"version":"4.3.1"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T00:00:00Z","timestamp":1701734400000},"content-version":"am","delay-in-days":338,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.ejca.2022.11.001","type":"journal-article","created":{"date-parts":[[2022,11,12]],"date-time":"2022-11-12T02:25:32Z","timestamp":1668219932000},"page":"28-47","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Immune-related generalised oedema \u2013 A new category of adverse events with immune checkpoint inhibitors"],"prefix":"10.1016","volume":"179","author":[{"given":"Maud","family":"Velev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barouyr","family":"Baroudjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxane","family":"Pruvost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"De Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane","family":"Laparra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samy","family":"Babai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Teysseire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois-Xavier","family":"Danlos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Albiges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Bernigaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc-Antoine","family":"Benderra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Prad\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Zaidan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Decroisette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma","family":"Fallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaelle","family":"Matergia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pernelle","family":"Lavaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Jantzem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5735-4905","authenticated-orcid":false,"given":"Marina","family":"Atzenhoffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Buyse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samy","family":"Ammari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Robert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0741-2118","authenticated-orcid":false,"given":"St\u00e9phane","family":"Champiat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Messayke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lien","family":"Marabelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Guettier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9leste","family":"Lebbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Lambotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3482-3331","authenticated-orcid":false,"given":"Jean-Marie","family":"Michot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2022.11.001_bib1","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.11.001_bib2","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2022.11.001_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.663088","article-title":"Pericardial toxicities associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database","volume":"12","author":"Ma","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ejca.2022.11.001_bib4","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.2169\/internalmedicine.7219-21","article-title":"Late-onset pleural and pericardial effusion as immune-related adverse events after 94 cycles of nivolumab","volume":"60","author":"Sawada","year":"2021","journal-title":"Intern Med"},{"key":"10.1016\/j.ejca.2022.11.001_bib5","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.annonc.2020.02.004","article-title":"Hepatic sinusoidal obstruction syndrome induced by nivolumab in advanced melanoma: a case report","volume":"31","author":"Charvet","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2022.11.001_bib6","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.cellimm.2018.01.003","article-title":"The biology of serous cavity macrophages","volume":"330","author":"Bain","year":"2018","journal-title":"Cell Immunol"},{"key":"10.1016\/j.ejca.2022.11.001_bib7","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1007\/s00262-022-03211-7","article-title":"Checkpoint-inhibitor induced polyserositis with edema","volume":"71","author":"Zierold","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ejca.2022.11.001_bib8","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/CJI.0000000000000217","article-title":"Immune-mediated pericarditis with pericardial tamponade during nivolumab therapy","volume":"41","author":"de Almeida","year":"2018","journal-title":"J Immunother"},{"key":"10.1016\/j.ejca.2022.11.001_bib9","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.lungcan.2021.03.015","article-title":"Pleural effusion is a negative prognostic factor for immunotherapy in patients with non-small cell lung cancer (NSCLC): the pluie study","volume":"155","author":"Epaillard","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejca.2022.11.001_bib10","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1111\/1759-7714.13399","article-title":"Pericardial tamponade during pembrolizumab treatment in a patient with advanced lung adenocarcinoma: a case report and review of the literature","volume":"11","author":"Harada","year":"2020","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.ejca.2022.11.001_bib11","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s40425-016-0185-2","article-title":"Recurrent pleural effusions and cardiac tamponade as possible manifestations of pseudoprogression associated with nivolumab therapy- a report of two cases","volume":"4","author":"Kolla","year":"2016","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2022.11.001_bib12","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1159\/000447053","article-title":"Nivolumab-induced pericardial tamponade: a case report and discussion","volume":"136","author":"Kushnir","year":"2017","journal-title":"Cardiology"},{"key":"10.1016\/j.ejca.2022.11.001_bib13","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.ijcard.2016.08.023","article-title":"Pericardial effusion with tamponade physiology induced by nivolumab","volume":"222","author":"Nesfeder","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ejca.2022.11.001_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2021-248099","article-title":"Cardiac tamponade as a presentation of primary adrenal insufficiency","volume":"15","author":"Page","year":"2022","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.ejca.2022.11.001_bib15","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3389\/fonc.2019.00004","article-title":"Pericardial effusion with tamponade in lung cancer patients during treatment with nivolumab: a report of two cases","volume":"9","author":"Yamasaki","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2022.11.001_bib16","doi-asserted-by":"crossref","first-page":"ytab002","DOI":"10.1093\/ehjcr\/ytab002","article-title":"Refractory constrictive pericarditis caused by an immune checkpoint inhibitor properly managed with infliximab: a case report","volume":"5","author":"Moriyama","year":"2021","journal-title":"Eur Heart J Case Rep"},{"key":"10.1016\/j.ejca.2022.11.001_bib17","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1016\/j.jtho.2019.02.003","article-title":"Systemic capillary leak syndrome (Clarkson's disease) as a complication of anti-programmed death 1 immunotherapy","volume":"14","author":"Lescure","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2022.11.001_bib18","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.kint.2016.11.029","article-title":"Capillary leak syndrome: etiologies, pathophysiology, and management","volume":"92","author":"Siddall","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.ejca.2022.11.001_bib19","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jaci.2018.09.001","article-title":"Characterizing drug-induced capillary leak syndromes using the World Health Organization VigiBase","volume":"143","author":"Mertz","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.ejca.2022.11.001_bib20","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/annonc\/mdv623","article-title":"Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper","volume":"27","author":"Champiat","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2022.11.001_bib21","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ejca.2021.08.048","article-title":"The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry","volume":"158","author":"Ruste","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2022.11.001_bib22","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ejca.2020.02.010","article-title":"The 2016-2019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical study","volume":"130","author":"Michot","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2022.11.001_bib23","first-page":"50","article-title":"The reorganisation of European pharmacovigilance. Part 2. From spontaneous reports to agency reviews and decisions","volume":"24","year":"2015","journal-title":"Prescrire Int"},{"key":"10.1016\/j.ejca.2022.11.001_bib24","first-page":"557","article-title":"[French pharmacovigilance database system: examples of utilisation]","volume":"50","author":"Moore","year":"1995","journal-title":"Therapie"},{"key":"10.1016\/j.ejca.2022.11.001_bib25","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S1246-7820(99)80036-6","article-title":"[Pharmacovigilance in practice]","volume":"6","author":"Spreux","year":"1999","journal-title":"Transfus Clin Biol"},{"key":"10.1016\/j.ejca.2022.11.001_bib26","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","article-title":"The medical dictionary for regulatory activities (MedDRA)","volume":"20","author":"Brown","year":"1999","journal-title":"Drug Saf"},{"key":"10.1016\/j.ejca.2022.11.001_bib27","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.4103\/jfmpc.jfmpc_831_21","article-title":"Agreement between WHO-UMC causality scale and the Naranjo algorithm for causality assessment of adverse drug reactions","volume":"10","author":"Shukla","year":"2021","journal-title":"J Family Med Prim Care"},{"key":"10.1016\/j.ejca.2022.11.001_bib28","doi-asserted-by":"crossref","first-page":"905","DOI":"10.4065\/mcp.2010.0159","article-title":"Idiopathic systemic capillary leak syndrome (Clarkson's disease): the Mayo clinic experience","volume":"85","author":"Kapoor","year":"2010","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ejca.2022.11.001_bib29","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1055\/s-2002-23204","article-title":"Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease)","volume":"22","author":"DeLeve","year":"2002","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.ejca.2022.11.001_bib30","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000023661","article-title":"Clinical characteristics of systemic lupus erythematosus with chylothorax and\/or chylous ascites: An analysis of 15 cases in China","volume":"99","author":"Zhang","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ejca.2022.11.001_bib31","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1177\/0961203318817831","article-title":"Chylous ascites and podocytopathy as the presentation of childhood lupus-an unusual occurrence","volume":"28","author":"Pilania","year":"2019","journal-title":"Lupus"},{"key":"10.1016\/j.ejca.2022.11.001_bib32","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/RHU.0b013e3182847260","article-title":"Chylous ascites and chylothorax as presentation of a systemic progression of discoid lupus","volume":"19","author":"Manzella","year":"2013","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.ejca.2022.11.001_bib33","first-page":"1330","article-title":"Concurrent occurrence of chylothorax, chylous ascites, and protein-losing enteropathy in systemic lupus erythematosus","volume":"29","author":"Lee","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ejca.2022.11.001_bib34","article-title":"Pseudo-pseudo Meigs' syndrome presenting with a combination of polyserositis, elevated serum CA 125 in systemic lupus erythematosus: a case report","volume":"98","author":"Gao","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ejca.2022.11.001_bib35","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/390831","article-title":"Chylous ascites and pleural transudate: rare presentations in systemic lupus erythematosus in old age","volume":"2012","author":"Chen","year":"2012","journal-title":"Case Reports Immunol"},{"key":"10.1016\/j.ejca.2022.11.001_bib36","first-page":"100","article-title":"[Chylous ascites revealing a systemic lupus erythematosus (L)]","volume":"31","author":"B'Chir Hamzaoui","year":"2007","journal-title":"Gastroenterol Clin Biol"},{"key":"10.1016\/j.ejca.2022.11.001_bib37","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/bmt.2015.52","article-title":"Sinusoidal obstruction syndrome\/veno-occlusive disease: current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation (EBMT)","volume":"50","author":"Mohty","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ejca.2022.11.001_bib38","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41409-019-0705-z","article-title":"Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: a position statement from an international expert group","volume":"55","author":"Mohty","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ejca.2022.11.001_bib39","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1073\/pnas.1414821112","article-title":"In\u00a0vivo albumin labeling and lymphatic imaging","volume":"112","author":"Wang","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ejca.2022.11.001_bib40","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1182\/blood-2015-10-676924","article-title":"Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure","volume":"127","author":"Richardson","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2022.11.001_bib41","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1016\/j.bbmt.2016.07.001","article-title":"Defibrotide for the treatment of hepatic veno-occlusive disease: final results from the international compassionate-use program","volume":"22","author":"Corbacioglu","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.ejca.2022.11.001_bib42","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.bbmt.2013.10.014","article-title":"Improved survival with ursodeoxycholic acid prophylaxis in allogeneic stem cell transplantation: long-term follow-up of a randomized study","volume":"20","author":"Ruutu","year":"2014","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922013363?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922013363?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:38:22Z","timestamp":1760733502000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804922013363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":42,"alternative-id":["S0959804922013363"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2022.11.001","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune-related generalised oedema \u2013 A new category of adverse events with immune checkpoint inhibitors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2022.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}